Showing posts with label China. Show all posts
Showing posts with label China. Show all posts

Friday, January 18, 2013

Arsenic, Mercury, Lead and...

Governments should learn from the Charitable Recycling Programme

The mobile revolution has far outclassed land-lines, televisions, and even computers; and gained the unique nomenclature of being a Fast Moving Consumer Durable. The catch is that due to such mass penetration, cellphone waste is a big threat to the environment.

According to a research by global consulting firm Deloitte, discarded old handsets could poison the environment unimaginably as it is estimated that the world would have 8,000 tonnes of cell phone waste by the end of 2012; too many useless handsets are simply being thrown into wastebaskets. The worry becomes deeper once the figures hit you. In 2008, the number of handsets crossed the 4 billion mark. Six out of ten people carry a cell phone today across the world. Interestingly, the contribution of emerging economies is quite significant.

China has the highest number of cell phones with a whopping 634 million in 2008. India follows China with over 427.3 million in 2009. The third in line is the US with over 270 million handsets. Most amazingly, the number is exponentially increasing across regions, irrespective of the financial crisis. If not disposed off properly, these handsets are ticking time bombs as they contain toxic materials like copper, mercury, brominated flame retardants, lead, arsenic, and zinc. Even if they are dumped into landfill sites, the toxic substances would surely contaminate the ground water. It is imperative now to incorporate proper recycling programs involving different stakeholder groups, where the government machineries globally work hand in hand with manufacturers to ensure and fine irresponsible disposal of cell phones.


Source : IIPM Editorial, 2012.
An Initiative of IIPMMalay Chaudhuri
and Arindam Chaudhuri (Renowned Management Guru and Economist).

For More IIPM Info, Visit below mentioned IIPM articles.
2012 : DNA National B-School Survey 2012
Ranked 1st in International Exposure (ahead of all the IIMs)
Ranked 6th Overall

Zee Business Best B-School Survey 2012
Prof. Arindam Chaudhuri’s Session at IMA Indore
IIPM IN FINANCIAL TIMES, UK. FEATURE OF THE WEEK
IIPM strong hold on Placement : 10000 Students Placed in last 5 year
IIPM’s Management Consulting Arm-Planman Consulting
Professor Arindam Chaudhuri – A Man For The Society….
IIPM: Indian Institute of Planning and Management
IIPM makes business education truly global
Management Guru Arindam Chaudhuri
Rajita Chaudhuri-The New Age Woman
IIPM B-School Facebook Page
IIPM Global Exposure
IIPM Best B School India
IIPM B-School Detail

IIPM Links
IIPM : The B-School with a Human Face
IIPM – FLP (Flexi Learning Program)

Monday, July 30, 2012

Anjan Sen, Director, Strategy & Operations, Deloitte India

B&E: Sector wise breakup of M&A deals in India for Q1 2011 shows that healthcare accounted for 25% of the total deal value. What were the possible factors favouring this sector?
AS:
One of the major factors behind this is the population (currently 1.2 billion). By 2030, India is expected to overtake China as the world’s most populous nation. As the middle class rises, opportunities in healthcare will also improve. Increased liberalization has allowed additional opportunities to emerge such as the private insurance market.

B&E: What are the various challenges with East-West alliances, and do India to India mergers make better sense?
AS:
There are some normal cultural and regulatory challenges associated with all cross-continental M&A deals. Drivers for M&A remain the same, whether East-West or domestic – access to innovation and R&D capabilities, reducing cost structures and improving manufacturing capabilities, entering new markets and product/service categories. MNCs have turned to Indian pharma companies for a combination of these factors – MNC-India pharma partnerships work well due to synergies obtained by both parties from leveraging different strengths across the drug development life cycle from R&D and manufacturing (typically strong in India) through sales and distribution (typically strong in US/EU).

B&E: Will pharma companies continue to pursue acquisitions of innovative biotech products and companies in future? If yes, what would be your suggestions for such deals?
AS:
India’s high skill resource pool and comparatively low costs make it an attractive base for pharma players looking to add biotech/vaccines to their portfolio. The biotech sector is expected to touch $10 billion by 2015, with revenues of $4 billion in 2010-11, and a 33% growth yoy. Although a relatively smaller sector currently, India’s biotech role will mature in the global market as the standard of living, knowledge base and the cost of doing business increase. One way of maintaining the cultural integrity of the acquired biotech firm is by allowing them to function as a separate company, while at the same time streamlining shared services to reduce operational costs.